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Re: Submission of invited review  
 
Dear Dr Waters, 
 
In response to our email exchange on the 26th of June, please find enclosed our invited review manuscript 
entitled “The life cycle of the Mu-opioid receptor” to be considered for publication in Trends in Biochemical 
Sciences. 
The present review synthesizes the current knowledge about the life cycle of the mu-opioid receptor (MOR). 
MORs are an undisputed target for the treatment of pain. They are the G protein-coupled receptor (GPCR) 
that mediates the effects of clinically used opioids such as morphine and fentanyl. Moreover, MOR is also a 
prototypical GPCR, where the new pharmacological, signalling and cell biology concepts have been 
discovered and demonstrated. These include pioneering structural studies, allosterism, biased agonism, 
endosomal and compartmentalised signalling and ligand-directed trafficking. While several reviews have 
focussed on particular aspects of these new developments, to our knowledge, there is no review that 
summarizes how MORs are synthesised, trafficked to and from the plasma membrane, how these 
mechanisms impact their eventual function and, finally, how all these mechanisms are affected in 
pathophysiological conditions such as pain or drug abuse. 
We think this review will provide a refreshed view to life cycle of a classical and important GPCR and can be 
used as a reference for researchers that are novices in the research area of opioid receptor biology as well 
as for more experienced researchers in need of a concise and entertaining read on the birth and death of a 
key therapeutic target in the treatment of pain.  
We would like to suggest the following reviewers: 
Dr Lakshmi Devi (lakshmi.devi@mssm.edu ) Professor of Pharmacology and Systems Therapeutics, , Icahn 
School of Medicine  at Mount Sinai. Opioid receptor pharmacologist with expertise in dimerization and 
modifications of opioid receptors.  
Dr Marta Filizola (marta.filizola@mssm.edu  ) Professor of Pharmacological Sciences and Neuroscience, Icahn 
School of Medicine at Mount Sinai. GPCR computational biologist with expertise in opioid receptors 
Dr John Streicher (jstreicher@email.arizona.edu ) – Assistant Professor in Pharmacology and Neuroscience, 
The University of Arizona Health Sciences. Opioid pharmacologist and cell biologist. 
Finally, please note that, despite our efforts of only citing 80 references in the main text, we are currently 
citing 87 publications. We are happy to consider removal of references upon editor or reviewer’s request. 
 
Thank you for your consideration of this manuscript. 
 
Sincerely,      
Meritxell Canals, PhD 
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Acting Trends Reviews Editor 
 
Revision of manuscript: TIBS-D-20-00173 
 
Dear Dr. Waters, 
We thank the Reviewers and the Editor for their positive and valuable comments, which have helped 
us improve our manuscript entitled “The life cycle of the Mu-Opioid Receptor”. We have now 
completed the revision of the manuscript, taking all of the Reviewers' comments into account. Please 
see the detailed responses below (blue text). New manuscript text is in red.  
Please also note that to address the comments of the Reviewers we have altered the wordcount and 




Dr. Cuitavi and co-authors presented a vibrant review on MOR life cycle. I found that presentation 
has few essential missing items from my point of view which I outlined below. 
Page 3 -" In humans the OPRM1 gene is in the sixth chromosome (6q25.2) and contains 9 exons". 
Not a true statement. The major isoform of OPRM1 is coded by 4 exons, but OPRM1 has many 
alternatively spliced forms such as 2 exons (usually named 2nd and 3d)  are very conservative and 
at least 19 exons (some with multiple splicing sites) shuffled into over 30 transcripts in humans, and 
in mice, at least 18 exons are combined into over 50 transcripts (NCBI-RefSeq, Ensembl, UCSC 
Genome Browser). Because the number of receptors constantly increasing, one should look at the 
latest edition of Ref-Seq or latest manuscripts, for example  PMID: 30066306. The same applied 
for page 5 sentence "However, the extensive alternative splicing of the OPRM1 gene (generating 
23 splicing variants, including 4 that do not encode protein)". Again, both human and mouse 
OPRM1 have many more than 23 splicing variants – 
Response to Reviewers
We have updated these numbers in the corresponding sections as well as cited the references 
suggested by the Reviewer. 
Page 5  - "The second group swaps exon 1 for exon 11, which results in 6-TM domains". The 6TM 
variants in both mouse and human also forms by several other splicing events with several other 
exons. For example PMID: 25485963, but also authors should also check with the newest updates 
on (NCBI-RefSeq, Ensembl, UCSC Genome Browser).  
We have edited this sentence to highlight that the 6-TM variants can be formed by other exons and 
the reference suggested by the Reviewer has been cited.  
Page 5. "The pharmacology of the MOR". The hyperalsgesic function of 6TM is not discussed. For 
example, its contribution to opioid induced hyperalgesia, but also few other evidence. For example 
PMID: 26657998  
We have added discussion on the potential role of 6-TM MOR splice variants in OIH, the potential 
cellular mechanisms that mediate these effects as well as potential strategies to prevent them (e.g 
through β2-ARs antagonists). The reference suggested by the Reviewer has been added. 
Page 6. "there is evidence that MOR heterodimerisation with ORL1, KORs and DORs" There is 
also evidence that MOR forms heterodimer with ADRB2 PMID: 26657998  
We apologise that we did not make this point clear. Our intention was to mention heterodimers 
within the opioid receptor family. Indeed, MOR heterodimerises with other GPCRs, including 
adrenoceptors, dopamine and cannabinoid receptors. A statement and a reference clarifying this 
have been added.  
Pages 6 and 7, when authors discuss the expression of MOR on the plasma membrane, I found no 
concrete discussion on receptor stabilization and  translocation which i believe very import part of 
receptor life cycle. Also, no discussion if/how 6TM and 1TM isoform reach the cell surface, though 
they are presented on the figure 3. 
Discussion on stabilization and translocation of the receptor to the cell surface was indeed included 
and referenced in the text apart from presented in figure 3. However, we have added statements 
clarifying how the 6-TM variants reach (or not) the plasma membrane.  
Pages 6 and 7. The authors describe analgesic function of MOR and function of abuse and misuse. 
They did not mention opioid induced hyperalgesia.  
A paragraph discussing the function of MOR in OIH has been added at the end of the section 
“MOR at work: a freshman at the cell membrane” 
Reviewer 2 
It's a thoughtful review with an interesting setting to describe MOR through its life cycle. The review 
covers a wide range of research data from various aspects of MOR regarding its regulations, 
functions and signaling pathways at DNA, RNA and protein levels. Overall, it's a good review. 
Some minor issues need to be addressed. 
1.     OPRL1 should be changed to ORL-1 in the second paragraph of The dark side of opioid pain 
relief, which would be consistent with MOR/DOR/KOR.  
Abbreviation for the Opioid Receptor Like-1 has been changed.  
2.     Human OPRM1 contains more than 9 exons as showed in reference # 29 with alternative 
splicing. Ref# 4 was an early review.  
This section has been corrected and edited as per this comment and that of Reviewer 1. 
3.     "commonly occurring" in the second paragraph of A new beginning: --" referring rs1799971 
is inaccurate, which can be changed to "mostly studied".  
This has been edited 
4.     The authors indicated that "some reports suggest that the rs1799971 SNP interferes with the 
analgesic power of some opioid". But there were no references.  
A reference for this statement has been added.  
5.     Using both OPRM1 and Oprm1 is unnecessary. If the authors want to indicate both human and 
rodent mu opioid receptor genes, it should be spelled out. As related, the authors	should	consider	
including	 a	 paragraph	 describing	 similarities	 and	 differences	 in	 structure,	 regulation	 and	
functions	between	human	and	rodent	mu	opioid	receptor	genes	and	proteins.		
We feel we should adhere to gene nomenclature. The text clearly explains the different 
nomenclature for the different species; “The MOR is encoded by the OPRM1 gene in humans and 
the Oprm1 gene in mice, and it is conserved across species.” We would appreciate the editor’s 
guidance for this point. We will revise the text if required.  
As per the Reviewer’s suggestion we have now included a brief paragraph mentioning the 
similarities and differences between human and rodent MOR. 
6.     In micrRNAs paragraph, some references were missing. For example, a reference for mir-
103/mir-107 in regulating expression of MOR1A was not cited.  
Discussion and references to these miRNAs have been added.  
7.     Recently, MOR crystal structures with antagonist or agonist configuration, as well as allosteric 
modification, have been resolved, providing important information how mu ligands interact with 
the receptor and induce signaling. The authors should include some discussion on this subject.  
We refer the Reviewer to Box 1 of our original manuscript, where we discuss all these subjects.  
8.     When described the mesocorticolimbic system, the authors only mentioned VTA an NAc. 
However, many literatures demonstrated the importance of prefrontal cortex in motivation and 
reward. Including this region is appropriate for a complete system.  
Discussion on the role of MORs in the PFC has been added and references included. 
9.     The authors should be carefully for the cited references. For example, ref# 45 and 74 were not 
right.  
References have been updated and revised. 
10.     Recently, TRV-130 (Olinvyk) was approved by FDA as an intravenous opioid to treat 
moderate to severe acute pain in adults. The authors may modify the discussion of TRV-130.  
Discussion of TRV-130 has been updated to reflect recent approval by FDA.  
11.     In The decline after a life of service, the authors mostly reviewed beta-arrestin2 and G protein 
signaling, which appeared not fitting into the theme. The authors can consider moving this section 
to the early section, and include degradation vs recycling after internalized. Von Zastrow has 
recently published several nice papers to describe how intracellular compartments play a role in 
signaling transduction. It can be fit quite well at this section.  
We thank the Reviewer for pointing out the omission of the most recent work of the lab of Mark 
Von Zastrow that clearly shows the different mechanisms of MOR regulation operating in pre- vs 
post-synapses. This has now been included and referenced.  
However, we feel that the discussion of G protein vs arrestin bias fits in this part of the manuscript 
rather than the section above. The role of β-arrestins in negatively regulating MOR is well 
established, hence our decision to include the description of β-arrestin-mediated processes in this 
section. However, we feel that for completeness, it is also important to highlight how initial 
observations of differential MOR regulation stemmed the field of biased agonism at this receptor, 
triggering a revolution in drug discovery that has recently been challenged. We therefore think that 
this discussion fits in this part of the manuscript and is a thought-provoking way of ending this 
review.   
Editorial comments 
Please remove the headings from the figure images e.g. Figure 1, Figure 2 (top left-hand corner). 
Headings have been removed.  
Please label the figure for Box 2 ‘Figure I’. The figure labelling for text boxes is not continuous 
thus the first figure in each text box is Figure I (the second figure in a text box is Figure II).  
This has been addressed  
Please replace the key word ‘Mu Opioid Receptor’ with a suitable alternative (this will improve 
searchability of your article).  
Key words have been updated 
Please label your final section Concluding remarks (currently: CONCLUDING REMARKS AND 
FUTURE PERSPECTIVES).  
Final section has been renamed 
Please double check your references. For example, I notice that the citation for reference 19 is 
incomplete, as is 17 and 52. Where you have an instance of ‘published ahead of print’, reference 
66, please provide as much information as possible, such as month of acceptance. Please also label 
reference 66 ‘Epub ahead of print’, and any others this applies to.  
References have been updated and revised.  
We appreciate the time spent by the Reviewers and the Editor and hope that the revisions made will 
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ABSTRACT 
Opioid receptors are undisputed targets for the treatment of pain. Unfortunately, targeting 
these receptors therapeutically poses significant challenges including addiction, dependence, 
tolerance and the appearance of side-effects such as respiratory depression and constipation. 
Moreover, misuse of prescription and illicit narcotics has resulted in the current opioid crisis. 
The mu-opioid receptor is the cellular mediator of the effects of most commonly used opioids 
and is a prototypical G protein-coupled receptor (GPCR) where new pharmacological, signalling 
and cell biology concepts have been coined. This review summarises our knowledge of the life 
cycle of this therapeutic target including its biogenesis, trafficking to and from the plasma 
membrane, and how the regulation of these processes impacts its function and is related to 



















THE DARK SIDE OF OPIOID PAIN RELIEF 
In the last couple of decades, the USA has experienced what is now known as “the opioid 
epidemic”. This devastating situation started due to the indiscriminate prescription of 
therapeutic opioids to ease painful conditions, suffered by approximatively 30% of US citizens. 
It is estimated that 3-26% of chronic pain sufferers treated with opioids become addicts and 61% 
of drug-overdoses in 2014 in the USA involved pharmaceutical opioids. Many countries in the 
world have followed the path of the USA, with Canada having a similar prevalence of opioid 
misuse and other countries, such as the United Kingdom and The Netherlands, reporting an 
increase in opioid misuse and overdose.  
In light of these events, research on the biology of opioid receptors (ORs), the cellular mediators 
of opioid-induced effects, has gained significant momentum. Since their discovery in the second 
half of the 20th century, many techniques have been used to study ORs; from radioligand binding 
in the 1970s and in situ hybridisation and molecular cloning in the 1990s [1], to the most recent 
visualisation of these receptors and their signalling in vitro and in vivo [2]. Of the four ORs 
subtypes [Mu (MOR), Delta (DOR), Kappa (KOR) and Opioid Receptor-Like 1 (ORL-1)], the MOR 
stands out for its role in opioid-induced analgesia and reward processing [3]. MORs play key 
roles in pain management, euphoria, sedation, miosis, addiction, truncation rigidity, nausea, and 
respiratory control in the central nervous system (CNS). Therefore, changes in their structure or 
function have significant consequences on those behaviours. Herein, we review the life cycle of 
the MOR, and engage the reader with the journey of this receptor, from its birth (biogenesis) to 
its death (degradation), highlighting the most relevant variations and disruptions along the way.  
 
A NEW BEGINNING: A MESSENGER IS BORN 
The four OR subtypes are part of the rhodopsin-like G protein–coupled receptors (GPCRs) 
superfamily and are 60% identical to each other. The greatest identity is found in the regions 
that encode for the 7-transmembrane domain and intracellular loops (70-90%), while the areas 
encoding for their N- and C-termini as well as the extracellular loops are more divergent. The 
MOR is encoded by the OPRM1 gene in humans and the Oprm1 gene in mice, and it is conserved 
across species. In humans the OPRM1 gene is in the sixth chromosome (6q25.2) and contains at 
least 19 exons [4]. The rodent and human MOR share 94% sequence identity, with the N-
terminus of the receptor being the area of highest divergence (with 65% sequence identity) [5]. 
This overall high sequence similarity explains why, to date, no significant differences in the 
structure, pharmacology and function have been reported across these species.   
Single-Nucleotide Polymorphisms (SNPs) in the coding regions of the MOR have been widely 
studied, linked to alterations in signalling and suggested to underlie altered responses to opioids 
[6]. The rs1799971 SNP, located at position 118 in the exon 1 of the OPRM1 gene, is the most 
studied and it encompasses the change of an adenine (A) to a guanine (G). Interestingly, the G-
containing allele is present in 15-30% of Europeans, 40-50% of Asians and 1-3% of Latinos and 
African Americans [7]. At a protein level this SNP results in a change of amino acid at position 
40, located in the N-terminus of the receptor; from an asparagine (Asn, N) to an aspartate (Asp, 
D). This N40D change removes a potential site for asparagine-linked glycosylation, which has 
been suggested to alter MOR affinity for different ligands, its transduction cascade [8] as well as 
the half-life of the receptor at the membrane [9]. Moreover, G118 adds a methylation site, which 
has been reported to result in a reduction of the levels of MOR messenger RNA (mRNA) [10]. 
Both alteration on glycosylation profiles as well as changes in the methylation patterns can 
 
 
disrupt the normal activity of the receptor. Some reports suggest that the rs1799971 SNP 
interferes with the analgesic power of some opioids [11]. However, the effect of this SNP 
depends on the type of pain and/or opioid analgesic under evaluation [12]. Numerous groups 
have also investigated the relationship between this polymorphism and postoperative reactions 
to anaesthesia such as vomiting, nausea, dizziness and pruritus, albeit with some discrepancies 
[13, 14]. As in the case of opioid-induced side effects, there is contradicting data with regards to 
the effects of this SNP in alcoholism [15], nicotine addiction [16], heroin misuse and relapse [17], 
and gambling [18]. Interestingly, pain and reward processing are not the only behaviours 
reported to be affected by the rs1799971 SNP. Indeed, this SNP has been assessed for the role 
that MORs play in the Hypothalamic–Pituitary–Adrenal (HPA) axis, including stress, separation 
anxiety [7], aggressive behaviours [19] , and suicidal ideation [20].  Finally, other SNPs have also 
been associated with pathological conditions related to MOR signalling (Figure 1). 
OPRM1 and Oprm1 transcriptional regulation has been previously reviewed by Wei and Loh [21]. 
Under normal conditions, MORs are expressed mainly in the CNS, the HPA axis and the testis. 
Both the human and the mouse genes are regulated by two promoters; the distal and the 
proximal promoters, with the latter accounting for approximatively 95% of the transcriptional 
activity [21]. These regions contain many GpC sites that can be epigenetically modified [22] 
(Figure 2A). It has been shown that when these promoters are highly methylated, the expression 
of the OPRM1/Oprm1 gene is supressed [23] and in the organs where the receptor is expressed, 
these GpC sites are usually unmethylated or hypomethylated.  
Methylation of the CpG sites of the OPRM1 promoter has been associated with several 
pathological conditions. OPRM1 promoter hypermethylation is related to the risk for alcohol 
dependence [24]. Interestingly, a specific CpG cluster form the OPRM1 promoter has been 
shown to be altered by naltrexone treatment of alcohol dependence in an age and ethnicity-
dependent way [22]. Increased DNA methylation in the OPRM1 gene is also associated with 
opioid dependence. The OPRM1 promoter is hypermethylated in blood cells of opioid addicts. 
This methylation pattern is conserved in the sperm, suggesting an epigenetic heritability of 
opioid abuse or dependence phenotypes [25]. Increased OPRM1 promoter methylation has also 
been reported in blood cells of males with opioid use disorder [26],  in lymphocytes of former 
heroin addicts treated with methadone [27] and has been associated with worse neonatal 
abstinence syndrome outcomes [28].  
The decrease in MOR expression caused by an increased OPRM1 promoter methylation may 
account for dampened responses to endogenous and exogenous opioids.  High methylation 
levels have been used as a biomarker to predict acute and chronic postsurgical pain [29], and 
Oprm1 silencing in primary sensory neurons of the Dorsal Root Ganglia has been observed under 
neuropathic pain conditions. Finally, OPRM1 promoter methylation has been investigated in the 
context of Alzheimer’s disease (AD) with increased methylation detected in AD patients [30]. 
Intriguingly, MOR activation has recently been shown to attenuate Aβ oligomer‑ induced 
neurotoxicity, suggesting another biomarker for AD diagnosis. 
The OPRM1/Oprm1 promoter can be epigenetically regulated by other modifications apart from 
DNA methylation. For example, histone acetylation and methylation have also been described 
to regulate OPRM1 expression in global ischemia patients [31]. Nonetheless, epigenetics is not 
the only mechanism that participates in OPRM1/Oprm1 transcription. Transcriptional factors 
that enhance (positive) or repress (negative) gene expression also play important roles in MOR 
expression (Figure 2B). In their extensive review, Wei and Loh list all the positive and negative 
transcriptional factors for mouse and human µ-opioid receptor gene [21].  
 
 
While epigenetics and transcriptional factors control OPRM1/Oprm1 transcription, once the 
mRNA is transcribed, it must reach its maturity by undergoing further regulatory mechanisms 
that will further influence the levels of the final protein product. 
 
MATURE BUT NOT ENOUGH 
Alternative splicing is commonly seen across GPCRs. However, the extensive alternative splicing 
of the OPRM1 gene (generating  more than 30 splice variants) is unusual and conserved in 
rodents and human [4, 32]. There are three main groups of OPRM1 isoforms according to the 
number of transmembrane (TM) domains of the resulting protein (Figure 2C). The first group is 
the one with the traditional 7-TM domains structure. Proteins in this group preserve exons 1, 2 
and 3 and differ on the exon with the STOP codon (C-terminal tail of the protein). The second 
group predominantly swaps exon 1 for exon 11, which results in 6-TM domains. However, some 
studies suggest that there are other exons that might also form 6-TM variants [33]. Finally, the 
last group only has 1-TM domain and the isoforms within it are non-functional. Expression of 
these isoforms is region specific in the brain [34] and their distribution differs between sexes 
[35].  
The pharmacology of the MOR splice variants has been thoroughly investigated, most 
prominently by the groups of Pasternak and Pan [36, 37].  Generally, opioids produce analgesia 
through 7-TM variants. However, it has been suggested that morphine uses both 7-TM and 6-
TM variants whereby 7-TM activation would trigger analgesia, reward, and respiratory 
depression, while chronic 6-TM activation participates in opioid-induced hyperalgesia (OIH), 
tolerance, and dependence. In this context, heteromerisation of 6-TM variants with the β2-
adrenoreceptors (β2-ARs) has been suggested to contribute to OIH and in rodent models, it has 
been proposed that β2-ARs antagonists can efficiently block the hyperalgesic effects induced by 
6-TM activation  [38]. Endomorphin analogues and buprenorphine [39] have also been shown 
to act through 7-TM and 6-TM isoforms to produce analgesia. Drugs that only activate 6-TM 
such as 3-iodobenzoyl naltrexamine have been shown to have reduced side-effects while 
keeping their therapeutic potential [40], suggesting that bias towards a specific MOR isoform is 
a promising avenue for potential therapeutic interventions that may avoid the classical opioid 
adverse effects. 
MicroRNAs (miRNAs) provide an additional regulatory mechanism for the OPRM1. Interestingly, 
morphine upregulates let-7 miRNA expression in neuroblastoma-like cells and in a mouse model 
of opioid tolerance. Let-7 supressed MOR translation without altering OPRM1 transcription [41], 
a let-7 miRNA inhibitor partially reduced morphine-induced antinociceptive tolerance, and 
miRNAs members of the let-7 family were upregulated in plasma after oral hydromorphone or 
oxycodone administration in humans [42], supporting the relationship between let-7 miRNAs 
and tolerance. miR-132 and miR-212 are miRNAs expressed in tandem [43] and regulated by the 
cAMP-response element binding protein (CREB). In zebrafish, morphine has been shown to 
regulate the miR-212/132 cluster, which in turn represses OPRM1 mRNA translation [44]. Other 
miRNAs that can alter MOR mRNA stability upon opioid treatment or in different pain conditions 
have also been reported, including miR-16 in lymphocytes [45], miR-134 in SH-SY5Y cells and 
Dorsal Root Ganglia [46] and miR-339-3 in the hippocampus [47]. Some miRNAs have been 
shown to regulate the mature mRNA of a specific MOR isoform. For example, chronic morphine 
treatment upregulates miR-103 and miR-107 in the striatum of morphine-tolerant mice, which 
in turn, specifically upregulates the isoform MOR-1A [48]. Chronic morphine treatment also 
 
 
increases miR-378a-3p expression in the brainstem of morphine tolerant mice, which in turn, 
decreases the expression of the MOR-1B3 and the MOR-1B4 isoforms [49]. 
After alternative splicing and miRNA regulation, the mRNA reaches its maturity. Since GPCRs are 
plasma membrane proteins, the OPRM1 messenger is translated by ribosomes located on the 
rough endoplasmic reticulum (ER) at the surface of the plasmatic membrane. The OPRM1 mRNA 
5’-untranslated region (UTR) contains four AUG codons. The first and the third AUG codons can 
function efficiently to initiate translation, however, translation from the third AUG negatively 
affects OPRM1 expression at the level of translation [50]. It has also been suggested that the 
weak expression of MOR under normal conditions is due to re-initiation mechanisms.  
Upon translation, MOR must be correctly folded. It has been suggested that the 1-TM isoforms 
act as chaperones for the 7-TM isoforms, facilitating their correct folding in the ER [51]. Several 
reports suggest that the 6-TM variants of MOR have altered subcellular expression and may 
require co-expression with other proteins (such as ORL-1 or β2-ARs) to reach the plasma 
membrane [33]. Moreover, hydrophobic ligands such as naloxone or etorphine can act as 
pharmacological chaperones helping the newly synthesised receptors to adopt their correct 
conformation and reach the plasma membrane [52] (Box 1).  
MORs can undergo four different post-translational modifications (PTMs): glycosylation, 
palmitoylation, phosphorylation and ubiquitination, which have recently been reviewed by 
Duarte and Devi [53]. In this section we will briefly describe the two PTMs that occur before and 
facilitate the anchorage of the receptor into the plasma membrane (Figure 1). Glycosylation 
consists of the attachment of sugar molecules to a protein that will be located in the plasma 
membrane or secreted. In the ER, monosaccharides covalently attach to what will be the 
extracellular part of the protein and formation of more complex glycans occurs in the Golgi 
apparatus [54].  There are 5 asparagine residues located at the N-terminal of the MOR that can 
potentially be glycosylated (N-glycosylation). Interestingly, the MOR has been suggested to have 
brain-region specific glycosylation levels [55]. As mentioned above, the A118G polymorphism of 
the OPRM1 gene eliminates Asn40 and, therefore, a key site of glycosylation. This has been 
suggested to reduce the half-life of the receptor at the membrane [9] and alter MOR binding 
and signalling properties [8]. The other PTM that occurs just after MORs translation is 
palmitoylation, namely the covalent union between a palmitate group and a cysteine through a 
thiol bond. It occurs in the ER and contributes to GPCR normal functioning by facilitating their 
incorporation to the plasma membrane. At the mMOR, Cys170 (Cys172 in hMOR), in TM3, has 
been reported to be a palmitoylation site, contributing to the interaction with cholesterol at the 
membrane and facilitating MOR homodimerisation [56].  
 
MOR AT WORK: A FRESHMAN AT THE CELL MEMBRANE 
The plasma membrane is the classical site of action of GPCRs like MORs. MORs bind a great 
variety of ligands (Box 2) and the consequences of their activation depend on the ligand itself as 
well as the site of action within the cell and the organism. Once at the membrane, the minimal 
functional unit of the MOR has been demonstrated to be a monomer [57]. However, MORs can 
form homodimers [58] as well as heterodimers with other opioid receptor subtypes as well as 
with other GPCRs. There is evidence that MOR heterodimerisation with ORL-1, KORs and DORs 
can alter MOR-induced responses in vitro and in vivo [59]. Moreover, other GPCRs such as β2-
ARs, and dopamine and cannabinoid receptors, have also been shown to heterodimerise with 
MORs [60]. Nonetheless, further research is required to support the physiological functions of 
MORs heterodimers and whether they represent potential therapeutic targets. 
 
 
The classical signalling cascade triggered by the MOR is through the activation of inhibitory G 
proteins (Figure 3A). MOR activation results in neuron hyperpolarisation and an inhibition of 
neuronal firing which is crucial in the modulation of pain sensation. MORs are widely expressed 
at different levels in the pain pathway, from somatosensory neurons of the Dorsal Root Ganglia 
[61], dorsal horn (DH) nociceptive neurons (including excitatory interneurons and neurons from 
lamina I from the anterolateral tract) to brain areas of the descending modulatory pathway [62]. 
In the DH, when MORs are activated, there is an inhibition of neuropeptide release (Substance 
P and CGRP), which promotes analgesia. However, the major sites for the analgesic properties 
of MOR agonists are the periaqueductal gray and the rostral ventromedial medulla. These two 
areas of the descending modulatory pain pathway are characterised by two different 
populations of neurons that enhance (on-cells) or attenuate (off-cells) pain sensation by 
modulating DH nociceptive neurons activity. Because of the different locations of the MOR, in 
the on-cells or in inhibitory neurons controlling off-neurons activity, in both cases, the activation 
of MOR leads to analgesia [63]. 
MOR regulatory function of the mesocorticolimbic system (MCLS) is prominent in motivation, 
reward, and aversion. This system is composed of many interconnected brain regions, including 
canonical dopaminergic pathways. MOR inhibition of GABAergic neurons from the Ventral 
Tegmental Area (VTA) is key for the role of this receptor in processing the reward, not only from 
stimuli of natural reinforcers such as food, drink, social interaction, and sex, but also from opioid 
and alcohol addiction [64]. Those neurons inhibit VTA dopaminergic neurons that fire to Nucleus 
Accumbens (NAc). Therefore, when MORs are activated in these neurons, they cannot fire and 
dopamine is released in NAc, an event that is essential to process reinforcement [65-67]. 
Furthermore, MORs can also be found in NAc, and its specific location in this area encodes for 
reward or aversion [68]. In addition, the activation of MORs located in NAc increases social 
interaction and might also be crucial to understanding psychiatric disorders that involve social 
impairment [69]. MOR is also expressed in the prefrontal cortex (PFC). However, while it is still 
not known exactly where MORs are located within the complex neural network in this brain 
area, research suggests that their activation leads to the excitation of glutamatergic pyramidal 
neurons through a disinhibition mechanism. It is also interesting to notice that MOR 
upregulation and signalling in the PFC might increase the responsiveness towards opiate-like 
drugs and natural rewards. In fact, MOR activation in PFC may also account for food-seeking 
behaviour and increased alcohol drinking in rats. Moreover, MORs in PFC also seem modulate 
inhibitory control and impulsivity, since MOR knockout mice, and rats treated with a MOR 
antagonist show decreased impulsivity while carrying out various tasks [70]. 
There is accumulating evidence that relates painful conditions to drug abuse and misuse. 
Interestingly, MORs play a role in this comorbidity since, even though pain and reward are 
opposed processes [71], they both need MORs [3, 61]. In fact, pain negatively impacts on 
motivation by altering the MCLS normal functioning [72-74]. Inflammatory pain blunts neuronal 
activation induced by intra-VTA DAMGO administration in some VTA projecting areas. 
Therefore, inflammatory pain induces MOR desensitisation in VTA, which is relevant for 
addictive behaviours [73]. Interestingly, Hipólito and collaborators discovered that MORs from 
the MCLS were desensitised in animals that suffered inflammatory pain and had a previous 
history of heroin consumption. This alteration promoted relapse into heroin consumption [72]. 
Finally, prolonged use of opioids can also lead to OIH, a significant clinical problem that defines 
a state of nociceptive sensitisation and is characterised by a paradoxical response whereby a 
patient receiving opioids to treat pain becomes more sensitive to certain painful stimuli. The 
 
 
precise molecular mechanisms underlying OIH are not yet understood and are the subject of 
intense study [75]. 
 
THE DECLINE AFTER A LIFE OF SERVICE 
Following activation, MORs undergo rapid phosphorylation, which triggers a decline in their G 
protein signalling as well as the recruitment of proteins that will result in receptor internalisation 
(Figure 3B). Phosphorylation of the MOR and its impact on receptor desensitisation and 
internalisation has been widely studied [76, 77]. While this phosphorylation is mostly mediated 
by G protein receptor kinases (GRKs) [78], there is also evidence that other intracellular kinases 
such as Ca2+/calmodulin-dependent protein kinase (CAMK)II, protooncogene tyrosine-protein 
kinase (Src), and protein kinase C (PKC) can phosphorylate the receptor [53]. Importantly, the 
phosphorylation barcode, as well as its signalling consequences, are highly dependent on the 
ligand bound to the MOR. Sequential and hierarchical phosphorylation of MORs results in the 
recruitment of the cytosolic protein β-Arrestin. MOR phosphorylation and β-arrestin 
recruitment result in MORs desensitisation, namely the uncoupling of the G protein signalling 
cascades, which has been proposed to be the initial step leading to opioid tolerance [79].  
MOR can recruit β-arrestin1 and 2 isoforms, although this seems to be agonist-dependent. While 
β-arrestins are essential to initiate MORs endocytosis via clathrin-coated pits, not all ligands that 
recruit arrestins induce robust receptor internalisation. This differential ability of agonists to 
induce receptor internalisation has been linked to the phosphorylation barcodes mentioned 
earlier [76, 77]. As with other GPCRs, β-arrestins have also been suggested to participate in MOR 
signalling [80], although the physiological relevance from this signalling is still not fully 
understood [81]. Moreover, β-arrestin1 can promote MOR ubiquitination by acting as E3-
ubiquitin ligase adaptors [53]. This ubiquitination is also ligand-dependent (occurs with high 
efficacy ligands such as DAMGO, but not with morphine) and results in degradation of the MOR 
within the lysosomes. However, MOR is not always degraded after endocytosis. Instead, and as 
opposed to the DOR, internalised MORs are usually recycled back to the plasma membrane, in 
a process known as resensitisation [82]. Each MOR isoform has been suggested to have different 
recycling rates and the mechanisms underlying receptor recycling are starting to be elucidated 
[83]. More recently, elegant microscopy studies have provided unprecedented insight into the 
mechanisms of MOR internalisation and recycling in presynaptic terminals, and how it differs 
from the classical internalisation-resensitisation paradigms that operate post-synaptically [84]. 
It is clear that MOR internalisation, recycling, and degradation are processes related to the 
development of tolerance. However, the molecular and cellular mechanisms, as well as the 
neural circuits changes which lead to reduced opioid responsiveness are just starting to be 
unravelled [85].  
Interestingly, the regulatory mechanisms of MOR have been the focus of intense research in an 
attempt to generate opioid analgesics devoid of, or with limited, side effects. In addition to 
tolerance, opioid treatment also results in significant respiratory depression, constipation, 
dependence, and addiction. Thus, efforts to separate the therapeutic and adverse effects of 
MOR agonists have dominated drug discovery at this receptor. These efforts were spearheaded 
by the observation of enhanced and prolonged morphine-induced analgesia and decreased 
tolerance in β-arrestin2 knockout mice, presumably due to decreased receptor desensitisation 
[86, 87]. These β-arrestin2 knockout mice were later shown to display decreased morphine-
induced respiratory depression and constipation [88]. This finding then led to investigations 
 
 
focused on the discovery of MOR agonists that would avoid the “β-arrestin pathway” while still 
promoting G protein signalling; namely G protein-biased agonists [89].  
There are now numerous descriptions of MOR G protein biased agonists. While some of these 
descriptions are limited to observations in recombinant cell lines, others have been tested in 
vivo, showing promising results. TRV130 (oliceridine, Olinvyk) has been the only new opioid 
agonist that has reached clinical trials and FDA applications [90], and was recently approved for 
the management of moderate to severe acute pain. SR17018 and mitragynine pseudoindoxyl 
are other compounds that have shown decreased opioid-induced side effects in pre-clinical 
models [91, 92]. However, there is now mounting evidence that suggests that while these 
compounds may still provide improved therapeutic profiles, the mechanism underlying these 
profiles is unlikely to be linked to an arrestin-dependent signal. Perhaps the most significant 
evidence is that derived from studies revisiting the initial hypothesis in β-arrestin2 knock-out 
mice which shows that morphine-induced respiratory depression is independent of β-arrestin2 
signalling [93]. Additionally, in knock-in mice expressing a MOR unable to recruit β-arrestin (by 
deletion of the phosphorylation sites that facilitate this recruitment), the opioid side effects of 
respiratory depression, constipation and withdrawal are exacerbated while only tolerance 
seems to be diminished [94].  In light of this data, the classical pharmacological concepts of 
partial agonism and low intrinsic efficacy have been proposed as potential explanations for the 
different therapeutic windows of the so-called G protein biased opioids [81, 95, 96]. Finally, it is 
important to highlight that while this research has focused on the development of tolerance, 
respiratory depression, and constipation, most of the novel opioids described as biased still 
result in significant abuse liability [97]. 
 
CONCLUDING REMARKS 
From birth as an mRNA to death as a heavily modified protein, MORs are essential for many vital 
activities. However, these events can be thwarted by genetic variations, alterations in expression 
patterns, and changes in MOR signalling and regulation.  While research has provided invaluable 
information that sheds light on MORs function, in many aspects we are still partially blind and 
further research is needed to untangle the ins and outs of the MOR life cycle and how it changes 
in diseased conditions. MOR hetero- and homodimerisation, pain comorbidities, biased/partial 
agonism, MOR isoforms and their role in neuroinflammation, chronic pain, and other 
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Dimer: Protein complex formed by two proteins. Homodimers contain two identical protomers 
while heterodimers contain two different protomers. 
 
 
Histone acetylation: Addition of an acetyl residue to N-terminal tail lysines of the histone core 
mediated by the histone acetyltransferase enzyme. This modification eases the DNA-histones 
interaction, facilitating transcription. Histone acetylation can be reversed by the action of the 
histone deacetylase enzyme, which impedes DNA transcription. 
Histone methylation: Some amino acids from the histone core N-terminal tails can be 
methylated by methyltransferases. Depending on the methylated residue this epigenetic 
modification can be repressive or activating. 
Hypothalamic–Pituitary–Adrenal (HPA) axis: This axis that comprises the hypothalamus, the 
pituitary gland and the adrenal glands is part of the neuroendocrine system and its connection 
with the CNS. It plays a major role in stress management and steroid hormones production. 
Let-7 family: Let-7 was the first miRNA family discovered in humans, although it was first found 
in C. elegans, and is conserved across different species. 
Mesocorticolimbic system (MCLS): This system is a dopamine-dependent pathway that 
facilitates behaviours that lead to survival. It has been associated with the behaviour modulation 
for reward and motivation but also aversion. 
MicroRNAs (miRNAs): Single strand RNA that can regulate gene expression. miRNAs need to be 
transcripted and processed. Drosha and Dicer are two proteins with catalytic power and carry 
out miRNAs processing, the former within the nucleus and the latter in the cytoplasm. In 
between the action of each of them, exportin 5 takes the non-mature miRNA out of the nucleus. 
After being processed, miRNAs are incorporated to the RNA-induced silencing complex (RISC), 
which in turn, by complementary binding the 3’-UTR, sequester the mRNA which is then 
degraded by exonucleases. 
Re-initiation: Event that happens when ribosomes resume scanning and re-initiate at 
downstream sites when the first AUG is followed shortly by a frame terminator codon. 
Ubiquitination: This posttranslational modification requires three enzymes (E). E1-activating 
enzyme is the first of them and activates the ubiquitin molecule at its C-terminal by using ATP. 
Afterwards, an E2-conjugating enzyme binds the activated ubiquitin through a cysteine residue. 
Finally, an E3-ubiquitin ligase ends the process by transferring the ubiquitin to the substrate. 
Untranslated region (UTR): regions flanking the mRNAs coding region. Both the 3’-UTR and the 
5’-UTR regions play an important role in mRNA regulation and translation. 
β-Arrestin: cytosolic proteins with two crescent-shaped beta-sandwiches and a central crest 
that bind to phosphorylated GPCRs to promote receptor internalisation. For some GPCRs β-
arrestins have been proposed to scaffold the formation of signalling complexes. 
 
TEXT BOXES 
Box 1. Protein Structures of the mu-opioid receptor 
The first crystal structure of the MOR was first described in 2012 [98]. It belonged to a construct 
of the mouse MOR (where the third intracellular loop was replaced with a T4 lysozyme) bound 
to a morphinian-like antagonist. This structure showed the typical 7-TM organisation of the 
receptor and has been used for significant in silico drug discovery efforts [99]. In 2015, the crystal 
structure of an agonist-bound mouse MOR and a G protein mimetic nanobody (Nb39) was 
 
 
solved, representing the first active state structure of the OR family [100]. This structure and 
related NMR studies [101] revealed how agonist and G protein binding at the MOR induce a 
conformational change with conserved shifts in domain positioning characteristic of GPCR 
activation mechanisms. This change in receptor conformation, then facilitates the 
conformational changes in the Gαi G protein that permits nucleotide exchange. Finally, in 2018, 
Koehl et al. presented the cryo-electron microscopy structure of a DAMGO-bound MOR in 
complex with the Gαiβγ heterotrimeric protein in the nucleotide free state. This was one of the 
first structures of a GPCR- Gαi complex. While this active structure was almost identical to the 
one previously described by Huang et al. in 2015, it showed the receptor-induced changes in the 
Gαi protein conformation that permit signalling via GDP/GTP exchange [102].  
 
Box 2. Endogenous and exogenous ligands of the mu-opioid receptor 
Endogenous opioid peptides derive from the proteolytic cleavage of larger prepropeptides and 
they all can bind the MOR albeit with different affinities. β-endorphins have high affinity for 
MOR and are potent analgesics with long lasting effects. Furthermore, β-endorphins also 
participate in reward processing and drug addiction. Enkephalins (Met-enkephalin and Leu-
enkephalin) display higher affinity for DORs, although they also bind and activate MORs. 
Similarly, dynorphins, prototypical KOR ligands, can also bind MOR with low affinity.  Finally, 
endomorphins are potent and selective MORs agonists, even though the gene encoding for 
these tetrapeptides or their protein precursors have not been identified.  
MORs are also activated by multiple exogenous ligands. These include not only opioids but also 
metabolites of other substances such as alcohol. Morphine is one of the most used analgesic 
drugs in clinic and its actions have been widely proven to be mediated by the MOR [103]. 
Morphine derivatives such as codeine and oxycodone are also used for the treatment of mild 
pain and cough or severe pain respectively, although they still display common opioid side 
effects. Another family of drugs that can activate MORs are piperidine derivatives, among which 
the most common is fentanyl. Fentanyl and its derivatives are over a hundred times more potent 
than morphine and, thus, they are used to ease moderate to severe pain in clinic. However, they 
still present opioid-induced side effects and their recreational use mixed with other drugs of 
abuse has recently skyrocketed. Finally, methadone (R enantiomer) and buprenorphine are 
MOR agonists with different efficacies that are widely used as maintenance treatments for 
opioid addiction.  
Naloxone is the prototypical OR antagonist. It is one of the most widely used opioids, the primary 
treatment for overdose, and its use has been instrumental in understanding MOR actions in 
preclinical studies. Other antagonists such as β-funaltrexamine (β-FNA) are highly selective for 
MOR, however, their pharmacokinetic properties (e.g irreversible antagonist) represent 
significant caveats for their clinical use and it has mainly been used to study OR pharmacology.  
Drugs that undergo metabolic reactions within the organism can generate molecules that bind 
and activate MORs. For example, (R/S)-salsolinol is a tetrahydroisoquinoline that has been 
proposed as the ethanol fraction that binds MORs [104]. Studies suggest that (R/S)-salsolinol 
binding pose at the MORs is like that of morphine [105]. In vivo, salsolinol triggers a response in 






Figure 1. Human MOR structural SNPs and posttranslational modifications. Glycosylation 
occurs on the asparagine at position 40 whereas palmitoylation occurs on the cysteine at 
position 172 (C3.55). Figure adapted from Knapman and Connor (2015). 
Figure 2. OPRM1 regulation. A) GpC islands methylation by DNA methyltransferase. Cysteines 
get a methyl group, impeding TFs promoter recognition and transcription. B) Main exons of the 
OPRM1 gene with the three groups of splicing variants and exon 1 proximal (PP) and distal (DP) 
promoters regulation by transcriptional factors (TFs). Green spot TFs promote OPRM1 
transcription whereas red spot TFs inhibit it. Figure adapted from Wei and Loh (2011) and Puig 
and Gutstein (2017). C) MOR isoforms. The colours of the fractions within each isoform match 
the colours of the exons in Figure 2B. 
Figure 3. MOR life cycle. A) From DNA to its activation. MOR mRNA is transcribed and 
translocated to the rough endoplasmic reticulum in the ribosomes where translation occurs. 1-
TM splicing variant chaperons the 6-TM and 7-TM splicing variants. The latter undergoes 
posttranslational modifications in the Golgi apparatus and gets into the cell membrane. Upon 
the binding of an agonist, activation of MOR promotes dissociation of inhibitory Gαi and Gβγ 
protein subunits. Gαi subunits typically suppress adenylate cyclase (AC), resulting in decreases 
in intracellular cAMP. Presynaptically, Gβγ subunits inhibit voltage-gated calcium channel 
(VGCC) opening. Postsynaptically, Gβγ subunits activate G-protein inwardly rectifying potassium 
(GIRK) channels. Altogether, this results in reduced neurotransmitter release and membrane 
hyperpolarisation. MORs activation also triggers kinase cascades that end with the translocation 
to the nucleus of some transcriptional factors. B) MOR internalisation, recycling, and 
degradation. After MORs activation triggers the G protein-induced cascade, GRK recruitment 
and MOR phosphorylation occur. These events are followed by β-arrestin recruitment and 
receptor internalisation. Upon ligand and arrestin dissociation, MORs are either recycled to the 




 Can epigenetics, mRNA processing or post-translational modifications of the MOR gene 
or protein be targeted therapeutically for the generation of novel, safer analgesics? 
 Can epigenetic modifications in the OPRM1 triggered by painful conditions or a drug use 
disorder be reversed? 
 Can the methylation state of the OPRM1 promoter be used as a biomarker for the 
assessment of risk associated with substance use disorders? 
 What are the cellular mechanisms that explain the improved side effect profiles of novel 
opioids? 
 Do miRNAs represent a viable strategy for the treatment of opioid-tolerance? 
 What are the cellular and neuronal mechanisms controlling alterations of MORs in MSCL 





 Single-Nucleotide Polymorphisms of OPRM1 resulting in amino acid changes in the 
protein sequence (e.g N40D) may have effects in pain and reward processing.  
 Epigenetic changes, as well as positive and negative transcription factors, are key 
controllers of receptor expression.  
 Alternative splicing generates over 20 different isoforms of MOR with distinct 
pharmacological characteristics; these include isoforms with 7-TM, 6-TM and 1-TM. 
 MicroRNAs affect OPRM1 mRNA stability upon treatment with opioid drugs. 
 Ligand-dependent regulation of MOR has been the subject of intense research focussed 
on the development of improved analgesics. 
 Pain might be a risk factor towards drug addiction. The role of MORs in pain and reward 
processes highlights the role of this receptor in such comorbidity. 
Highlights
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